BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins for chronic diseases and immune-therapies. It is a cutting-edge and mature solution for oral formulations, not only for peptides, but also small molecules, novel protein scaffolds, nucleotides, domain antibodies, vaccines, immunotherapies etc.
1. BioLingus, the winner of the “Gamechanger Award” & “European Biotech Award from ACQ.
2. BioLingus wins Best Delivery System Award from the Global Health & Packaging magazine
3. BioLingus CEO Scoops Two Wins in Business Worldwide Magazine Awards.
4. Biolingus article in Business Worldwide Magazine.
Corporate Partnerships
To further exploit the potential of the BioLingus Technology, we are interested in exploring partnerships with other pharmaceutical companies. Aside from pharmaceutical companies, we are also interested in working with animal health companies" (with adjusted formulations) and food companies working on innovative food supplements.
Together we unlock the potential of the BioLingus Technology, and thus transform current standard practices in the administration of peptides and proteins.
